98%
921
2 minutes
20
Brain atrophy may precede symptoms in Alzheimer's disease (AD), but it remains unclear whether atrophy in this preclinical stage falls within a distinct brain network or is associated with transitional cognitive changes. We investigated cortical thickness in cognitively unimpaired older adults with varying amyloid-β accumulation and estimated the connectivity of each individual's atrophy pattern using a large normative connectome (n = 1000). A distinct network was connected to atrophy patterns in amyloid-β-positive (n = 1242) versus negative (n = 536) participants. This preclinical AD network was similar to a previously published atrophy network associated with AD dementia (r = 0.8284, p = 0.016). In leave-one-out cross-validation, atrophy patterns connected to the preclinical AD network were associated with lower cognitive performance (p = 0.0018), greater subjective cognitive decline (p < 0.001), and amyloid-β levels (p < 0.001). Atrophy in preclinical AD maps to a network similar to AD dementia that is associated with amyloid-β and cognition, demonstrating an atrophy-related network across the continuum of AD.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12083676 | PMC |
http://dx.doi.org/10.21203/rs.3.rs-5977523/v1 | DOI Listing |
Introduction: Plasma glial fibrillary acidic protein (GFAP), a marker of astrocytic activation, has been linked to Alzheimer's disease; however, its prognostic value in cognitively unimpaired (CU) individuals remains unclear.
Methods: We included 949 CU older adults from the A4 preclinical AD trial, and its companion LEARN cohort. Baseline plasma GFAP was measured, and longitudinal associations with cognitive decline, clinical dementia rating (CDR) progression, and imaging biomarkers were assessed over 240 weeks.
J Pediatr Surg
September 2025
Hospital de Clínicas de Porto Alegre (HCPA), Rua Ramiro Barcelos, 2350, Santa Cecília, 90035-003, Porto Alegre, Rs, Brazil; Universidade Federal do Rio Grande do Sul (UFRGS), Rua Ramiro Barcelos, 2400, Santa Cecília, 90035-003, Porto Alegre, RS, Brazil.
Background: Obstructions of the tracheobronchial tree can result from various etiologies. Most cases of tracheal stenosis or tracheomalacia are associated with patient-specific anatomical and functional abnormalities, making treatment challenging. Despite progress in the development of tracheal support devices, the optimal or near-optimal stent design remains elusive.
View Article and Find Full Text PDFHum Gene Ther
September 2025
Institut de Neurociències (INc), Universitat Autònoma de Barcelona (UAB), Barcelona, Spain.
Gene therapy is emerging as a transformative approach for treating amyotrophic lateral sclerosis (ALS), a progressive and fatal neurodegenerative disease. While gene replacement has shown a groundbreaking success in spinal muscular atrophy, the complexity of ALS-due to frequent gain-of-function mutations and a heterogeneous etiology-presents significant challenges. Importantly, approximately 90% of ALS cases are sporadic, with unknown genetic mutation, further complicating patient stratification and therapeutic targeting.
View Article and Find Full Text PDFWorld J Methodol
December 2025
Third Academic Department of Orthopaedics, Papageorgiou General Hospital, Thessaloniki 56403, Greece.
Background: Massive rotator cuff tears (RCTs) result in impaired shoulder function and quality of life. These tears lead to structural changes in the rotator cuff muscles, which compromise recovery after repair and increase re-tear rates.
Aim: To investigate the potential inhibitory effects of alpha-tocopherol (vitamin E) and OTR-4131 on muscle atrophy, fatty infiltration, and fibrosis in rotator cuff muscles following a massive RCT using a Wistar rat model, and establish a standardized methodology for evaluating potential therapeutic agents.
Alzheimers Dement
September 2025
Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA.
Introduction: In observational studies of preclinical AD, an arbitrary "baseline" can obscure where an individual is located along a theoretical continuum. Optimizing longitudinal trajectories can distill multiple, non-linearly distributed observations into a single metric and inform where an individual may be along the disease course.
Methods: We developed a cognitive time (c-time) metric based on longitudinal cognitive data (mean = 7.